Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose ...
FMC-220 inhibits tumor cell viability across a panel of Y220C mutant cell lines and delivers tumor regression, including complete responses in p53 Y220C mutant CDX and PDX models, regardless of ...
The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS (ON) G12C-selective inhibitor, ...
Heroes of Labor began in 2012 in response to the exemplary work done by union leaders and members in the aftermath of Hurricane Sandy. These awards have been a tribute to the everyday champions of New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback